. 2021 Feb 15;22(4):1918. doi: 10.3390/ijms22041918

Table 2.

Association between CCL5 and the clinicopathological factors according to the C-C chemokine receptor 1 (CCR1), CCR3 and CCR5 status in breast carcinomas.

Clinicopathological Factors	CCR1-Positive Group			CCR3-Positive Group			CCR5-Positive Group
	CCL5 Status		p-Value	CCL5 Status		p-Value	CCL5 Status		p-Value
	Negative (n = 11)	Positive (n = 10)	p-Value	Negative (n = 43)	Positive (n = 29)	p-Value	Negative (n = 25)	Positive (n = 20)	p-Value
Stage
I	5	5	0.36	24	17	0.73	13	16	0.13
II	4	5		10	8		7	3
III	2	0		9	4		5	1
Pathological T Factor
pT1	6	8	0.22	27	20	0.60	14	17	0.037
pT2-4	5	2	0.22	16	9	0.60	11	3	0.037
Lymph Node Metastasis
Negative	7	5	0.53	30	19	0.70	15	18	0.024
Positive	4	5	0.53	13	10	0.70	10	2	0.024
Histological Grade
1 (well)	4	4	0.14	15	8	0.028	11	9	0.92
2 (intermediate)	5	1		22	9		10	7
3 (poor)	2	5		6	12		4	4
ER
Negative	2	3	0.53	6	10	0.040	4	7	0.14
Positive	9	7	0.53	37	19	0.040	21	13	0.14
PR
Negative	3	5	0.28	10	16	0.0057	4	8	0.070
Positive	8	5	0.28	33	13	0.0057	21	12	0.070
HER2
Negative	8	7	0.89	36	24	0.91	20	17	0.66
Positive	3	3	0.89	7	5	0.91	5	3	0.66
Ki67 LI (%) *	16 (1–30)	19 (1–37)	0.60	13 (1–53)	18 (1–44)	0.062	12 (1–53)	13.5 (1–47)	0.73
MVD *	28 (13–101)	30.5 (18–82)	0.84	23 (6–101)	36 (7–106)	0.044	28 (10–101)	27 (7–82)	0.62

* Data were presented as median (minimum–max). All other values represent the number of cases. p < 0.05 was considered significant and described in boldface, and 0.05 ≤ p < 0.1 was described in italic. ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, LI: labeling index, MVD: microvessel density and PR: progesterone receptor.